-
Sagent recalls injectable drugs again within the year due to the risk of sterility protection
Time of Update: 2022-01-12
Because of the risks found in the retained samples, the tightness of the container may not be able to guarantee sterility, Sagent Pharmaceuticals recalled Levetiracetam injection .
However, this is not the first time that the pharmaceutical company has recalled drugs due to tightness.
-
Bispecific antibody treatment of refractory HER2-positive breast cancer has positive clinical results
Time of Update: 2022-01-12
A few days ago, Zymeworks announced that its HER2 bispecific antibody zanidatamab, combined with chemotherapy, has shown encouraging results in a phase 1 clinical trial for the treatment of refractory HER2-positive breast cancer patients who have received multiple pre-treatments.
-
The new crown vaccine cannot replace the flu vaccine. The interval between the two vaccination is at least 14 days
Time of Update: 2022-01-12
" Wang Huaqing, chief expert of the Chinese Center for Disease Control and Prevention's immunization program, said that vaccination against the new crown virus cannot replace the flu vaccine, according to The technical guidelines for new coronavirus vaccination suggest that the interval between influenza vaccine and new coronavirus vaccination should be at least 14 days .
-
The interim results of the phase IIb trial showed that after subcutaneous injection of monoclonal antibody ASC22 treatment, persistent hepatitis B surface antigen disappearance was observed in patients with chronic hepatitis B
Time of Update: 2022-01-12
Gale is committed to the development and commercialization of innovative drugs in the fields of viral diseases, non-alcoholic steatohepatitis/primary biliary cholangitis, tumors (oral tumor metabolic checkpoints and immune checkpoint inhibitors) to solve domestic problems.
-
Potential first-in-class inhibitors targeting newly synthesized lethal targets will enter the clinic
Time of Update: 2022-01-12
On November 17, 2021, Mirati Therapeutics announced that it has submitted an IND application for a Phase 1/2 clinical trial to the US FDA to evaluate the PRMT5 inhibitor MRTX1719 for the treatment of methylthioadenosine phosphorylase (MTAP) deficiency The efficacy and safety of cancer .
-
Research has found that adding a little nanoparticle can greatly enhance the effect of anti-cancer therapy
Time of Update: 2022-01-11
According to the research published by him and his colleagues in Nature Nanotechnology, some clinical trials are currently adopting immune checkpoint inhibitors and some new immunotherapies to help treat MPE.
-
The clinical results of antisense oligonucleotide drugs to reduce the frequency of epileptic seizures in children by 70.6% are positive
Time of Update: 2022-01-11
▲The mechanism of action of STK-001 (picture source: Stoke's official website)The Phase 1/2a trial plans to enroll about 90 children and adolescents aged 2-18 years who are diagnosed with Dravet syndrome and have SCN1A gene mutations .
-
Feng Jie's laboratory published a paper in JOURNAL OF FUNCTIONAL FOODS
Time of Update: 2022-01-11
Title: Protective effect and mechanism of betaine against hyperosmotic stress in porcine intestinal epithelium ( IF=4.
104838 Publication time DEC 2021 Document Type Article Attachment: Full text link
-
Phase 3 clinical results of GSK/Medicago new crown plant-derived adjuvant vaccine candidate announced
Time of Update: 2022-01-11
Most of the published phase 3 efficacy trials of the currently licensed new coronary pneumonia vaccine were conducted when only the original virus was transmitted, and cannot be directly compared .
-
Research and development of rapid correction of hereditary gene mutations are expected to treat human genetic diseases
Time of Update: 2022-01-11
Recently, in a research report entitled "Simultaneous high-efficiency base editing and reprogramming of patient fibroblasts" published in the international journal Stem Cell Reports, scientists from the University of Helsinki and other institutions developed a new method through research.
-
Scientific interpretation: What is the difference between Aiweilan's Tongyan Needle and Rutianshi?
Time of Update: 2022-01-11
June 25, 2021Amic's "Cross-linked sodium hyaluronate gel containing L-lactic acid-glycol copolymer microspheres" has been approved by NMPA for marketing, and the product will be named "Nu Tianshi" .
-
Ascent Pharma’s Bcl-2 selective inhibitor APG-2575 for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma for the key registration phase II clinical study was approved by CDE
Time of Update: 2022-01-11
HK) announced today that the company is developing an original class 1 new drug Bcl-2 selective inhibitor lisaftoclax (APG-2575) for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL) /SLL)’s key registration phase II clinical study (APG2575CC201) was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration .
-
How can cancer cells bypass treatment?
Time of Update: 2022-01-11
▲Cultivate yeast cells lacking Rad27 protein at different temperatures (picture source: reference [1])As a result, the research team performed whole-genome sequencing on the mutant cells.
, Error-prone, stress-induced 3′ flap–based Okazaki fragment maturation supports cell survival, Science(2021).
-
Shp2: Potential star anti-cancer targets may promote cancer?
Time of Update: 2022-01-11
Overall, the study found that tumor cells need Shp2 to accelerate the development of HCC, which validates and strengthens the theory that Shp2 is a new ideal target for cancer treatment, but at the same time, removing Shp2 from liver cells can also make Myc carcinogenic.
-
The prospect of experimental mRNA AIDS vaccine is promising
Time of Update: 2022-01-11
Science and Technology Daily, Beijing, December 9th (Reporter Zhang Mengran) Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) said that an mRNA-based experimental HIV vaccine shows promise in mice and non-human primates .
-
The top three issued equipment procurement announcements: as long as domestically produced
Time of Update: 2022-01-11
Among them, the Zhejiang Provincial Department of Finance announced the "2021-2022 Provincial Government Procurement of Imported Products Unified Demonstration List (Medical Equipment)" notice.
There are 195 types of medical equipment included in the unified demonstration list of imported products purchased by the Zhejiang Provincial Government .
-
FDA today approves innovative hepatitis B adult vaccine targeting multiple viral antigens for the first time
Time of Update: 2022-01-11
On December 1, 2021, VBI Vaccines announced that the US FDA has approved the third-generation hepatitis B virus (HBV) vaccine PreHevbrio (Sci-B-Vac) to be used to prevent all known HBV in adults 18 years and older Infections caused by subtypes .
-
First-line treatment of lung cancer failed!
Time of Update: 2022-01-11
According to the data published at the ESMO Virtual Conference on Immuno-oncology, in the first-line treatment of non-small cell lung cancer (NSCLC) patients whose tumors express PD-L1 (CPS ≥ 1%), compared with Keytruda monotherapy, “immunity + targeting” "The combination Keytruda+Lenvima failed to prolong the life of the patient .
-
Geriatric Oncology Breakthrough!
Time of Update: 2022-01-11
The analysis results of a group randomized trial of 718 elderly patients (the trial name is GAP70+) showed that the treatment Geriatric evaluation (such as physical activity, multiple medications, coexisting diseases, functional status, nutrition, cognition, social support, and psychological status) beforehand can not only effectively influence clinical treatment decisions, but also help elderly patients manage other coexisting diseases .
-
How to improve poor skin?
Time of Update: 2022-01-11
The beauty of the skin is closely related to the health of the body.
Sleeping time has health effects on all parts of the body.
